UK Study Finds Autoimmune Disorders Affect Around One in Ten People
According to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read moreAccording to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read moreMyMD Pharmaceuticals, Inc.®, a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
Read moreThe European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreTezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read morePfizer has reported that the Japanese Ministry of Health, Labour and Welfare (MHLW) authorized CIBINQO® (abrocitinib), a novel therapy for
Read moreEctica Technologies is delighted to announce it will be presenting as a corporate sponsor at the upcoming CHI Conference on
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreJanssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read moreIrish biotechnology firm Inflazome announced today that it has closed a share purchase agreement with Swiss pharma giant Roche in
Read moreThe widely used arthritis medicine Actemra (tocilizumab) has demonstrated “excellent effects” in the treatment of the COVID-19 disease. Roche’s promising
Read more